NO20064183L - Less immunogenic binding molecules - Google Patents

Less immunogenic binding molecules

Info

Publication number
NO20064183L
NO20064183L NO20064183A NO20064183A NO20064183L NO 20064183 L NO20064183 L NO 20064183L NO 20064183 A NO20064183 A NO 20064183A NO 20064183 A NO20064183 A NO 20064183A NO 20064183 L NO20064183 L NO 20064183L
Authority
NO
Norway
Prior art keywords
amino acid
binding molecules
molecules
nucleic acid
acid sequence
Prior art date
Application number
NO20064183A
Other languages
Norwegian (no)
Inventor
Peter Kufer
Ralf Lutterbuese
Birgit Kohleisen
Ulla Lenkken-Schuetz
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05715354A external-priority patent/EP1716178B1/en
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NO20064183L publication Critical patent/NO20064183L/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelsen tilveiebringer et spesifikt bindingsmolekyl, hvor nevnte molekyl omfatter eller består av minst to domener hvorved ett av nevnte minst to domener spesifikt binder til/interagerer med det humane CD3-komplekset og det nevnte domenet omfatter en aminosyresekvens av en antistoff derivert lett kjede, hvor nevnte aminosyresekvens er en spesielt identifisert aminosyresekvens som omfatter spesifikke aminosyresubstitusjoner, og et andre domene er eller inneholder minst ett ytterligere antigen-interagerende-sete og/eller minst ett ytterligere effektordomene. Oppfinnelsen tilveiebringer videre nukleinsyremolekyler som koder for de bispesifikke bindingsmolekylene av oppfinnelsen, vektorer som omfatter nevnte ukleinsyremolekyler og vertsceller transformert eller transfektert med nevnte vektorer. Videre angår oppfinnelsen en fremgangsmåte for produksjonen av bispesifikke bindingsmolekyler av oppfinnelsen og sammensetninger som omfatter de bispesifikke bindingsmolekylene av oppfinnelsen, nukleinsyremolekylene av oppfinnelsen eller vertscellene av oppfinnelsen.SUMMARY The present invention provides a specific binding molecule, wherein said molecule comprises or consists of at least two domains wherein one of said at least two domains specifically binds to / interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain , wherein said amino acid sequence is a specifically identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one additional antigen-interacting site and / or at least one additional effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors. Furthermore, the invention relates to a process for the production of bispecific binding molecules of the invention and compositions comprising the bispecific binding molecules of the invention, the nucleic acid molecules of the invention or the host cells of the invention.

NO20064183A 2005-02-16 2006-09-15 Less immunogenic binding molecules NO20064183L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05715354A EP1716178B1 (en) 2004-02-16 2005-02-16 Less immunogenic binding molecules
PCT/EP2005/001573 WO2005077982A1 (en) 2004-02-16 2005-02-16 Less immunogenic binding molecules

Publications (1)

Publication Number Publication Date
NO20064183L true NO20064183L (en) 2006-11-08

Family

ID=37564058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064183A NO20064183L (en) 2005-02-16 2006-09-15 Less immunogenic binding molecules

Country Status (1)

Country Link
NO (1) NO20064183L (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US11472886B2 (en) 2008-10-01 2022-10-18 Amgen Research (Munich) Gmbh Cross-species-specific PSMAxCD3 bispecific single chain antibody

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US11472886B2 (en) 2008-10-01 2022-10-18 Amgen Research (Munich) Gmbh Cross-species-specific PSMAxCD3 bispecific single chain antibody

Similar Documents

Publication Publication Date Title
DK1716178T3 (en) Less immunogenic binding molecules
CY1121536T1 (en) HUMAN ANTIBODIES AGAINST ALPHA-SYNUCLEIN
CY1118303T1 (en) SPECIFICATION FOR CROSS-CUTTING SINGLE SPECIAL SINGLE-SINGLE ANTIBODY PSMAXCD3
DK1752471T3 (en) Synthetic immunoglogulin domains with binding properties that are modified in regions of the molecule that differ from the complementarity determining regions
NO20091283L (en) Human antibodies that bind CXCR4 and its applications
MX2009013328A (en) Methods of modifying antibodies, and modified antibodies with improved functional properties.
NZ717429A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CY1116525T1 (en) BINDING STRENGTHENING FACTORS
CL2011000084A1 (en) Monoclonal antibody or antigen binding fragment thereof that binds to human cytomegalovirus (hcmv); nucleic acid molecule that encodes it; vector; host cell; Method of production; and composition that understands it.
NO20083268L (en) Antibodies designated for HER-3 and uses thereof
AR060583A1 (en) ANTIBODY OF HUMANIZED C- KIT
NO20092285L (en) Human monoclonal antibodies to BTLA and methods of use
NO20090406L (en) Antigen-binding molecules that bind EGFR, vectors encoding these, and uses thereof
DK1819830T3 (en) Methods for antibody generation
BRPI0812878C1 (en) isolated antibody or functional part thereof, vector, method for producing an antibody or a functional part thereof, for producing an antibody-producing cell and for producing an antibody capable of specifically binding to rsv, composition, and use of an antibody or functional part of it or of a composition or vector
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
MX2009009450A (en) He4 monoclonal antibodies and methods for their use.
NO20064866L (en) IRTA-5 antibodies and their use
TR201909531T4 (en) ANTI-IL-17 ANTIBODIES USING ANKILOSANE SPONDILITE TREATMENT METHODS
TN2011000253A1 (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
ATE497508T1 (en) ANTIBODIES DIRECTED AGAINST THE MAMMAL EAG1 ION CHANNEL PROTEIN
NO20071432L (en) Method for concentration of antibodies or therapeutic products thereof.
NO20081328L (en) Modified antigen-binding molecules with altered cell signaling activity
BR112012024964A2 (en) psmaxcd3 biospecific single chain antibody of specific cross species, their preparation process, their use, vector, pharmaceutical composition and kit
MX2009008608A (en) Monoclonal anti-cxcl13 antibodies.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application